PGXL Labs, AutoGenomics to expand molecular testing in pharmacogenetics
LOUISVILLE, K.Y.—PGXL Laboratories, a provider of pharmacogenetic testing and interpretive services, recently announced that it has established a collaborative partnership with AutoGenomics Inc., a developer of an automated, microarray-based multiplexing diagnostic platform, wherein they will utilize this platform—the automated INFINITI analyzer—for several different personalized medicine applications.
PGXL plans to utilize the INFINITI Warfarin and CYP450 2C19 Assay and the INFINITI KRAS-BRAF test.
PGXL Labs was the first CLIA-certified lab in the country to conduct pharmacogenetic tests. It provides pharmacogenetic testing and interpretive services and developed one of the first commercial CYP2C9/VKORC1 tests for accurate anticoagulant dosing. Along with its clinical practice, PGXL performs contract research for manufacturers of pharmaceuticals and medical equipment.
"The automation provided by the AutoGenomics' INFINITI Analyzer will enhance workflow in our laboratories," said Mark Linder, executive vice president of operations and co-founder of PGXL Labs, in a statement. "With their comprehensive menu of molecular applications in the pharmacogenetics arena, we have found AutoGenomics to be a very suitable partner in meeting our emerging testing needs."
A privately held company based in Vista, Calif., AutoGenomics' technology can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics.
"We are excited to partner with PGXL Labs, who have pioneered in bringing the benefits of pharmacogenetics testing to patients across the country," stated Ramanath Vairavan, senior vice president of AutoGenomics. "The versatility of our BioFilmChip Microarray technology allows us to rapidly develop new test applications to meet the evolving needs in companion diagnostic testing and enable PGXL Labs to expand the array of personalized medicine tests. "